Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells

Menopause

Volumn 17, Issue 5, 2010, Pages 1055-1063

  Mafuvadze, Benford ^a   Benakanakere, Indira ^a   Hyder, Salman M ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Apigenin; Breast Cancer; Hormone therapy; Menopause; Progestins; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; APIGENIN; ESTROGEN RECEPTOR ALPHA; GESTAGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; MIFEPRISTONE; PLACEBO; PROGESTERONE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APIGENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLAVONOIDS; HUMANS; PROGESTERONE CONGENERS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957694977     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181dd052f     Document Type: Article

References (32)

1. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
2. Chen WY, Hankinson SE, Schnitt SL, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-1500.
3. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer. Cancer Res 1998;58: 392-395.
4. Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 2001;92:469-473.
5. Benakanakere I, Besch-Williford C, Schnell J, et al. Natural and synthetic progestins accelerated 7, 12-dimethylbenz(a)anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin Cancer Res 2006;12:4062-4071.
6. Aldaz CM, Liao QY, LaBate M, Johnston DA. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcino-genesis 1996;17:2069-2072.
7. Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 2007;67:9929-9936.
8. Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 2006;13: 905-919.
9. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise [review]. Int J Oncol 2006;30:233-245.
10. Yin F, Giuliano AE, Law RE, Van Herle AJ. Apigenin inhibits growth and induces GM/2 arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 2001;21:413-420.
11. Wang W, VanAlstyne PC, Irons KA, Chen S, Stewart JW, Birt DF. Individual and interactive effects of apigenin analogs G2/M cell-cycle arrest in human colon carcinoma cell lines. Nutr Cancer 2004;48: 106-114.
12. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukemia HL-60 cells. Eur J Cancer 1999; 35:1517-1525.
13. Shukla S, Gupta S. Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory prostate carcinoma DU145 cells. Mol Carcinog 2004;39:114-126.
14. Hu X, Meng D, Fang J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Car-cinogenesis 2008;29:2369-2376.
15. Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle dere-gulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 2001;287:914-920.
16. Breinholt V, Hossaini A, Svendsen GW, Brouwer C, Nielsen SE. Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability. Food Chem Toxicol 2000;38:555-564.
17. Chen D, Landis-Piwowar KR, Chen MS, Dou QP. Inhibition of proteosome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res Treat 2007;9:R80
18. Fang J, Zhou Q, Liu L, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1> and VEGF expression. Carcinogenesis 2007;28:858-864.
19. Liang Y, Wu J, Stancel GM, Hyder SM. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol 2005;93:173-182.
20. Mirkin S, Wong BC, Archer DF. Effects of 17A-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and thrombospondin-1 messenger RNA in breast cancer cells. Int J Gynecol Cancer 2006;16:560-563.
21. Moore MR. A rationale for inhibiting progesterone-related pathways to combat breast cancer. Curr Cancer Drug Targets 2004;4:183-189.
22. Graham JD, Mote PA, Salagame U, et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 2009;150:3318-3326.
23. Liang Y, Benakanakere I, Besch-Williford CB, Hyder RS, Ellersieck M, Hyder SM. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause 2010;17: 1040-1047.
24. Carroll CE, Ellersieck MR, Hyder SM. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause 2008;15:570-574.
25. Jung YW, Hong EJ, Choi KC, Jeung EB. Novel progestogenic activity of environmental endocrine disruptors in the upregulation of calbindin-D9k in an immature mouse model. Toxicol Sci 2005;83:78-88.
26. Viswanath G, Halder S, Divya G, Majumder CB, Roy P. Detection of potential (anti)progestagenic endocrine disruptors using recombinant human progesterone receptor binding and transactivation assay. Mol Cell Endocrinol 2008;295:1-9.
27. Mueller MD, Vigne JL, Pritts EA, Chao V, Dreher E, Taylor RN. Progestins activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells. Fertil Steril 2003;79:386-392.
28. Ellmann S, Sticht H, Thiel F, et al. Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci 2009;66: 2405-2426.
29. Read L, Greene G, Katzenellenbogen B. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists and growth factors. Mol Endocrinol 1989;3:295-304.
30. Carroll CE, Benakanakere I, Besch-Williford C, Liang Y, Hyder SM. HIF-1> is required for both progestin-induced VEGF secretion by breast cancer cells and in vivo progression of progestin-dependent mammary tumors. Paper presented at: 100th Annual American Association of Cancer Research Meeting, April 18-22, 2009, Denver, Colorado.
31. Duval M, Bedard-Goulet S, Delisle C, Gratton J. Vascular endothelial growth factor-dependent downregulation of Flk-1/KDR involves Cbl-mediated ubiquitination. J Biol Chem 2003;278:20091-20097.
32. Rosenberg RS, Grass L, Jenkins DJA, Kendall CWC, Diamandis EP. Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines. Biochem Biophys Res Commun 1998;248:935-939.